An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2019
Price : $35 *
At a glance
- Drugs FB 825 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Fountain BioPharma
- 22 Feb 2019 Planned End Date changed from 31 Dec 2018 to 10 Apr 2019.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2017 New trial record